JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2026. Vol. 71. № 1
DOI:10.33266/1024-6177-2026-71-1-5-13
D.A. Kiseleva1, S.V. An’kov1, N.A. Zhukova1, M.S. Borisova1,
K.S. Bogatisheva1, T.G. Tolstikova1, M.A. Melchenco1, 2, O.I. Yarovaya1, 2
Radioprotective Effect of Ursolic Acid and Arabinogalactan Compositions in CD-1 Mice after a Single X-Ray Irradiation
1 N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Novosibirsk, Russia
2 Novosibirsk State University, Novosibirsk, Russia
Contact person: D.A. Kiseleva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Experimental evaluation of radioprotective effects of ursolic acid (UA) and arabinogalactan (AG) compositions in CD-1 mice after a single sub-lethal X-ray irradiation.
Material and methods: The study was conducted on outbred male CD-1 mice weighing 25–30 g. Single total irradiation was performed on X-RAD 320 X-ray at a dose of 5 Gy. Test substances and their compositions in different ratios were administered for two weeks before and four weeks after irradiation. The severity of radiation damage and treatment effects were assessed in dynamics by survival rate, body weight, hematological parameters of blood, histological examination of thymus, heart, liver, spleen, kidneys.
Results: After irradiation with a dose of 5 Gy, the mortality rate of animals in the NC, AG100, AG200, UA:AG100:100, UA:AG50:200, UA:AG100:400 groups were 50 %, in the UA100 group – 40 %, and in the UA:AG100:200 – 30 %. In addition, on the 28th day after irradiation, partial recovery of hematological parameters relative to intact control was observed in the groups UA50, UA100, AG100, AG200, UA:AG100:100, UA:AG50:100, UA:AG100:400. Application of the UA:AG100:200 composition contributed to a statistically significant recovery of leukocytes, erythrocytes and hemoglobin number from the 14th to the 28th day after irradiation in comparison with the negative control group, as well as the recovery on the 28th day after irradiation of all studied hematological blood parameters to the values of intact control. In irradiated animals that received UA individually and in combination with AG, positive dynamics of reparative processes were noted, which were manifested to a greater extent in liver and kidneys.
Conclusion: The inclusion of UА in a composition with AG at a dose of 100:200 mg/kg led to a decrease in the toxic effects of X-ray radiation on CD-1 mice body, namely, positive dynamics of hematological parameters of blood, reparative processes in liver and kidneys, as well as an increase in animal survival of up to 70 % compared with negative controls, which indicates the prospects for further studies of UA compositions effects in comparison with a registered radioprotective drug as a positive control against exposure to ionizing radiation.
Keywords: ursolic acid, arabinogalactan, radioprotective properties, X-ray exposure, mice
For citation: Kiseleva DA, An’kov SV, Zhukova NA, Borisova MS, Bogatisheva KS, Tolstikova TG, Melchenco MA, Yarovaya OI. Radioprotective Effect of Ursolic Acid and Arabinogalactan Compositions in CD-1 Mice after a Single X-Ray Irradiation. Medical Radiology and Radiation Safety. 2026;71(1):5–13. (In Russian). DOI:10.33266/1024-6177-2026-71-1-5-13
References
1. Montay-Gruel P., Meziani L., Yakkala C., Vozenin M.C. Expanding the Therapeutic Index of Radiation Therapy by Normal Tissue Protection. Br J Radiol. 2019;92;1093:20180008. Doi: 10.1259/bjr.20180008.
2. Maier P., Wenz F., Herskind C. Radioprotection of Normal Tissue Cells. Strahlenther Onkol. 2014;190:745-752. Doi: 10.1007/s00066-014-0637-x.
3. Васин М.В. Препарат Б-190 (индралин) в свете истории формирования представлений о механизме действия радиопротекторов // Радиационная биология. Радиоэкология. 2020. T.60. C. 378-395 [Vasin M.V. Drug B-190 (Indralin) in Light of the History of the Formation of Ideas about the Mechanism of Action of Radioprotectors. Radiatsionnaya biologiya. Radioekologiya = Radiation Biology. Radioecology. 2020;60:378-395 (In Russ.)]. Doi: 10.31857/S0869803120040128.
4. Dale D.C., Crawford J., Klippel Z., Reiner M., Osslund T., Fan E., Morrow P.K., Allcott K., Lyman G.H. A Systematic Literature Review of The Efficacy, Effectiveness, and Safety of Filgrastim. Support Care Cancer. 2018;26;1:7-20. Doi: 10.1007/s00520-017-3854-x.
5. Lee M., Yee J., Kim J.Y., Kim J.Y., An S.H., Lee K.E., Gwak H.S. Risk Factors for Neutropenia and Febrile Neutropenia Following Prophylactic Pegfilgrastim. Asia Pac J Clin Oncol. 2019;15;4:231-237. Doi: 10.1111/ajco.13152.
6. Kiseleva D.A., An’Kov S.V., Tolstikova T.G. Ursolic Acid: Sources, Synthesis, Properties, Modifications, Application. Russ J Bioorg Chem. 2025;51;2:508-532. Doi: 10.1134/S1068162024605974.
7. Liu Z., Jiao Y., Wang Y., Zhou C., Zhang Z. Polysaccharides-Based Nanoparticles as Drug Delivery Systems. Adv. Drug Deliv. 2008;60;15:1650-1662. Doi: 10.1016/j.addr.2008.09.001.
8. Медведева Е.Н., Бабкин В.А., Остроухова Л.А. Арабиногалактан лиственницы – свойства и перспективы использования (обзор) // Химия растительного сырья. 2003. №1. С. 27-37 [Medvedeva Ye.N., Babkin V.A., Ostroukhova L.A. Larch Arabinogalactan – Properties and Prospects for Use (Review). Khimiya Rastitel’nogo Syr’ya = Chemistry of Plant Raw Materials. 2003;1:27-37 (In Russ.)].
9. Kong R., Zhu X., Meteleva E.S., Polyakov N.E., Khvostov M.V., Baev D.S., Tolstikova T.G., Dushkin A.V., Su W. Atorvastatin Calcium Inclusion Complexation with Polysaccharide Arabinogalactan and Saponin Disodium Glycyrrhizate for Increasing of Solubility and Bioavailability. Drug Deliv Transl Res. 2018;8;5:1200-1213. Doi: 10.1007/s13346-018-0565-x.
10. Борисов С.А., Хвостов М.В., Толстикова Т.Г., Душкин А.В., Чистяченко Ю.С. Фармакодинамические исследования комплекса включения полисахарида лиственницы арабиногалактана с напроксеном // Сибирский научный медицинский журнал. 2017. Т.37. №4. С. 19-25 [Borisov S.A., Khvostov M.V., Tolstikova T.G., Dushkin A.V., Chistyachenko Yu.S. Pharmacodynamic Studies of the Inclusion Complex of Larch Polysaccharide Arabinogalactan with Naproxen. Sibirskiy Nauchnyy Meditsinskiy Zhurnal = The Siberian Scientific Medical Journal. 2017;37;4:19-25 (In Russ.)].
11. Khvostov M.V., Borisov S.A., Tolstikova T.G., Dushkin A.V., Tsyrenova B.D., Chistyachenko Y.S., Polyakov N.E., Dultseva G.G., Onischuk A.A., An’kov S.V. Supramolecular Complex of Ibuprofen with Larch Polysaccharide Arabinogalactan: Studies on Bioavailability and Pharmacokinetics. Eur J Drug Metab Pharmacokinet. 2017;42;3:431-440. Doi: 10.1007/s13318-016-0357-y.
12. Nguyen H.N., Ullevig S.L., Short J.D., Wang L., Ahn Y.J., Asmis R. Ursolic Acid and Related Analogues: Triterpenoids with Broad Health Benefits. Antioxidants (Basel). 2021;10;8:1161. Doi: 10.3390/antiox10081161.
13. Macià I Garau M., Lucas Calduch A., López EC. Radiobiology of the Acute Radiation Syndrome. Rep Pract Oncol Radiother. 2011;16;4:123-30. Doi: 10.1016/j.rpor.2011.06.001.
14. Horie K., Namiki K., Kinoshita K., Miyauchi M., Ishikawa T., Hayama M., Maruyama Y., Hagiwara N., Miyao T., Murata S., Kobayashi T.J., Akiyama N., Akiyama T. Acute Irradiation Causes a Long-Term Disturbance in the Heterogeneity and Gene Expression Profile of Medullary Thymic Epithelial Cells. Front Immunol. 2023;14:1186154. Doi: 10.3389/fimmu.2023.1186154.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was supported by the Russian Science Foundation (project No. 25-25-00119).
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.11.2025. Accepted for publication: 25.12.2025.